Influenza vaccine effectiveness in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16
Pere Godoy(Servicio Canario de la Salud), Ángela Domı́nguez(Instituto de Salud Carlos III), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), A. Bravo Romero(Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública), Mireia Jané(Generalitat de Catalunya), Núria Soldevila(Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública), Cristina Rius(Centro de Investigación Biomédica en Red), Joan A. Caylà, Núria Torner(Centro de Investigación Biomédica en Red)
Cited by 60
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
|Critical Care|2009|382
The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis
|The Lancet|2020|357
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348